Stocks and Investing
Stocks and Investing
Fri, June 28, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Nicole Germino Initiated (YMAB) at Strong Buy and Held Target at $21 on, Jun 28th, 2024
Nicole Germino of Truist Securities, Initiated "Y-mAbs Therapeutics, Inc." (YMAB) at Strong Buy and Held Target at $21 on, Jun 28th, 2024.
Nicole has made no other calls on YMAB in the last 4 months.
There are 3 other peers that have a rating on YMAB. Out of the 3 peers that are also analyzing YMAB, 0 agree with Nicole's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Nicole
- Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $22 on, Monday, May 13th, 2024
- Bill Maughan of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $26 on, Monday, March 4th, 2024
- Etzer Darout of "BMO Capital" Maintained at Buy with Increased Target to $26 on, Monday, March 4th, 2024
Contributing Sources